The Effect of Vinpocetine on the Clinical Outcome of Patients With Diabetic Nephropathy
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
The goal of this controlled, randomized, clinical trial is to evaluate the effect of vinpocetine on clinical outcomes on the diabetic nephropathy patients. The following will be evaluated; anthropometrics, kidney functions, glucose panel, lipid panel, ICAM-1, quality of life. Participants will receive either vinpocetine or placebo, twice daily for 3 months.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥ 18 years,
• Type II diabetic patients with CKD stage 3 (eGFR = 30 - 59 ml/min) or stage 4 (eGFR 15-29 ml/min),
• Albumin/Creatinine ratio (ACR): 30 - 300 μg /mg (microalbuminuria),
• Stable standard therapy for at least three months prior to inclusion in the study.
Locations
Other Locations
Egypt
Ain Shams Hospitals
RECRUITING
Cairo
Ain Shams University Hospital
NOT_YET_RECRUITING
Cairo
Contact Information
Primary
Tamer El Said
drtamer_elsaid@med.asu.edu.eg
201227366062
Time Frame
Start Date: 2024-07-10
Estimated Completion Date: 2025-06-01
Participants
Target number of participants: 64
Treatments
Experimental: Vinpocetine + Standard Therapy
Vinpocetine capsules, 30 mg, twice daily, with meals for 3 months
Placebo_comparator: Placebo + Standard Therapy
Placebo, twice daily, with meals for 3 months
Related Therapeutic Areas
Sponsors
Leads: Ain Shams University